Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus A case report

Medicine (United States)

Volumn 95, Issue 29, 2016, Pages

  Inadomi, Kyoko ^a   Kumagai, Hozumi ^a   Arita, Shuji ^b   Tsuruta, Nobuhiro ^a   Takayoshi, Kotoe ^a   Mishima, Koji ^a   Ota, Shun Ichiro ^a   Tanaka, Mamoru ^a   Okumura, Yuta ^a   Sagara, Kosuke ^a   Nio, Kenta ^a   Nakano, Michitaka ^a   Uchi, Hiroshi ^c   Yamamoto, Hidetaka ^d   Ariyama, Hiroshi ^a   Kusaba, Hitoshi ^a   Niiro, Hiroaki ^a   Oda, Yoshinao ^d   Akashi, Koichi ^a   Baba, Eishi ^b  

^a Graduate School of Medical Sciences   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Anemia; Melanoma; Nivolumab; Thrombocytopenia

Indexed keywords

CISPLATIN; DACARBAZINE; DOCETAXEL; FLUOROURACIL; METHYLPREDNISOLONE; NIVOLUMAB; PREDNISOLONE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ARTICLE; BI CYTOPENIA; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CASE REPORT; CHEMOTHERAPY INDUCED ANEMIA; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; ESOPHAGOSCOPY; ESOPHAGUS CANCER; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; MELANOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANEMIA; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; ESOPHAGEAL NEOPLASMS; FATALITY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; PATHOLOGY; SECONDARY;

AGED; ANEMIA; ESOPHAGEAL NEOPLASMS; FATAL OUTCOME; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; THROMBOCYTOPENIA;

EID: 84980027702     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004283     Document Type: Article

References (13)

1. Yano M, Shiozaki H, Murata A, et al. Primary malignant melanoma of the esophagus associated with adenocarcinoma of the lung. Surg Today 1998;28:405-8.
2. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9:587-95.
3. Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015;372:320-30.
4. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2:662-73.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
6. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65.
7. World Health Organization. Skin cancers. (Accessed May 12, 2015, Available at http://www.who.int/uv/faq/skincancer/en/index1.html.)
8. Chang AE, Karnell LH, Mench HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84, 836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664.
9. Kanameishi S, Otsuka A, Nonomura Y, et al. Idiopathic thrombocyto-penic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol 2016;27:546-7.
10. Kopecky J, Trojanová P, Kubecek O, et al. Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literature review. Jpn J Clin Oncol 2015;45:381-44.
11. Simeone E, Grimaldi AM, Esposito A, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 2014;8:240.
12. Gordon IO, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009;58:1351-3.
13. Ahmad S, Lewis M, Corrie P, et al. Ipilimumab-induced thrombocyto-penia in a patient with metastatic melanoma. J Oncol Pharm Pract 2012;18:287-92.